Today (November 11), the ninth batch of state-organized centralized drug procurement in Shanghai produced the results of the proposed selection. 6 kinds of drugs have been successfully procured in this centralized procurement, and the average price of the selected drugs will be reduced by 41%, which is expected to save 58.182 billion yuan in drug costs every year.
The ninth batch of state-organized drug centralized procurement, with 262 products from 382 enterprises participating in the bidding. 205 products from 266 companies have been qualified to be selected, including 200 products from 260 domestic pharmaceutical companies and 5 products from 6 international pharmaceutical companies (including 1 original drug and 5 imported generic drugs), and the proportion of bidders to be selected is about 78%, with an average of 6.5 companies per variety to be selected. The selection rate of the centralized procurement enterprises is high, and the effect of reducing the burden of the masses is good, and the balance of multiple goals of "reducing burden, promoting development, and ensuring supply" has been realized.
This centralized procurement covers drugs for common and chronic diseases such as infections, tumors, cardiovascular and cerebrovascular diseases, gastrointestinal diseases, and psychiatric diseases, as well as key drugs such as emergency rescue drugs and shortage drugs. After the patent expiration of lenalidomide capsules for the treatment of multiple myeloma in May 2023, it was included in the centralized procurement in a timely manner, and the average price of each capsule (5mg) was reduced from about 25 yuan to 200 yuan, which can save about 15,3880 yuan per month in drug costs, and the burden on patients is significantly reduced. The price of drugs under national key monitoring and rational use of drugs, such as rabeprazole oral regular-release dosage form for the treatment of gastrointestinal diseases and esomeprazole magnesium enteric-coated dry suspension, has been significantly reduced. Amiodarone injection for the treatment of arrhythmia, dopamine injection for rescue shock, oxytocin injection for inducing labor and other five kinds of shortage drugs and emergency rescue drugs, through the "volume" procurement method to stabilize enterprise expectations, to achieve a balance of multiple goals of guaranteed supply and reasonable price reduction.
Since 2018, the National Health Insurance Administration has organized nine batches of state-organized drug centralized procurement, including a total of 374 drugs, with an average reduction of more than 50%. In the next step, the National Health Insurance Administration will work with relevant departments to guide all localities and selected enterprises to do a good job in the implementation of the results of the selection, so as to ensure that patients across the country can use the selected products after the price reduction of this centralized procurement in March 2024.
(CCTV reporter Mu Yuanyuan, He Xueguo)